Similar Posts
Breast Cancer Chemotherapy – Here Is What Happened When Outrageous Prices Met The Free Market
Byadmin2Nine to twelve years. That’s about how long most drug companies have to make serious money on new products before their patent protection ends. Then, generic companies enter the fray and prices, typically, plummet. Yet, two decades after coming to market, Herceptin (a drug used to treat breast and stomach cancer) was still priced at…
The Question Isn't Whether We Are Overdiagnosing Cancer, But How Much
ByadminMedical experts now agree that as a result of aggressive screening programs, we have an epidemic of cancer overdiagnosis in the United States. With mammograms finding tiny cancers and PSA tests discovering unpalpable prostate cancers, we are now unearthing some cancers too early for our own good. What do experts mean by “overdiagnosis,” you ask?…
Should North Carolina Expand Medicaid?
ByadminMy home state of North Carolina is one of a number of states that refused to expand Medicaid, even though the Affordable Care Act stipulates that the federal government will cover the majority of expenses associated with such expansion. Here is an excellent story in the Fayetteville Observer laying out the issues: Denise Johnson works…
Want narcotics just ask for them?
ByadminA very disturbing new study was just published, in which physicians viewed a video of a patient with back pain asking for OxyContin. Twenty percent of docs said they would prescribe that med under that circumstance: …Too often, doctors prescribe potentially dangerous medications to patients who shouldn’t be getting them, and what they prescribe is…
Here’s Why Pharmaceutical Companies Raise Their Prices So Much
BypeterYes, I’ve ranted about healthcare prices before. On more than one occasion. But I have a new rant for you. It’s not about the high price of new drugs It’s not about a couple pharmo-bro CEOs hiking prices of generic medications by 4 or 5,000% It’s about brand name drugs already on the market, that,…
When It Comes to Cancer Screening, Are We All Nuts?
ByadminIn a recent Health Affairs article, David Asch and I wrote about how hard it can be to stop screening aggressively for things like breast and prostate cancer even when the evidence suggests we are doing more harm than good. Well, journalist Steven Petrow has a nice piece in the Washington Post looking at the…
